Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

Bivalent molecules are heterobifunctional molecules with three components: a protein-of-interest (POI) binding moiety, a linker, and an E3 ubiquitin ligase warhead. Bivalent molecules can hijack ...

Moderna has reported preliminary clinical results with a bivalent version of its COVID ... lasting protection compared to the original SpikeVax shot against all SARS-CoV-2 variants, including ...

Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax ... Moderna's first bivalent shot mRNA-1273. ...

The Massachusetts-based company said that third-quarter revenue from its Spikevax shot came in at $1.8 billion, with $1.2 billion of the sales coming in the United States. The overall figure ...

According to Reuters, the company earned $6.7 billion in revenue from Spikevax in 2023. Moderna has stated in the past that it is “not aware of any significant intellectual property impediments ...

Shares up nearly 5% to $54.22 in early trading Spikevax COVID vaccine sales reached $1.8 billion, beating expectations Moderna expects lower COVID vaccine sales this year compared to 2023 $10 ...

The lawsuits specifically concern Moderna’s COVID-19 vaccine, Spikevax, and its more recently approved mRNA shot for respiratory syncytial virus (RSV), mRESVIA. GSK claims Moderna is marketing ...

The lawsuit said, opens new tab Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger RNA into the human body.

Moderna earned US$6.7 billion (S$8.7 billion) in revenue from Spikevax last year. Pfizer made US$11.2 billion from sales of Comirnaty, the Covid vaccine it developed with German partner BioNTech.

According to the lawsuit, the development of Moderna’s COVID-19 vaccine, Spikevax, depended on key technological advancements made at Northwestern. Also Read: Alnylam’s Concedes Its Patent ...